Federal Official Gazette
No updates.
ANS news
No updates.
Open public consultations
- CP 163. Its purpose is to receive input on the proposed updates to the List of Health Procedures and Events (Rol), specifically on the preliminary recommendation of non-incorporation for the technologies covered by UAT No. 171 – Inclisiran, UAT No. 175 – Lebrikizumab and UAT No. 176 – Momelotinib. Deadline: Nov 5, 2025 to Nov 24, 2025
Scheduled public hearings
- Public Hearing No. 61, collection of input on the preliminary recommendation of non-incorporation for the following technologies:
(i) UAT 171 – Inclisiran for the treatment of primary hypercholesterolemia or mixed dyslipidemia;
(ii) UAT 175 – Lebrikizumab for the treatment of adult patients with severe atopic dermatitis who have failed, are intolerant to or have a contraindication to cyclosporine; and
(iii) UAT 176 – Momelotinib for the treatment of intermediate- and high-risk myelofibrosis.
Date: November 19, 2025, from 9 a.m. to 1 p.m.
Open public calls for input
There are no open public calls for input.
Open public calls
No updates.
Other news
US announces deal with makers of Mounjaro and Ozempic
Source: exame.com · read the full article
Sources: Federal Official Gazette (DOU) and the ANS website. Press items link to the original article. This brief is for information only and does not constitute legal advice.